Janux Therapeutics, Inc. JANX
17.82 USD +0.36 (+2.06%)
At closeNov 3, 2026, 4:06 PM EST
17.82 0.00 0.00%
After hours · Nov 3, 4:06 PM ET
17.59 Day range 18.00
12.18 52-week range 34.74
- YTD
- +29.13%
- 1 year
- -34.89%
Financial health
Altman Z-Score
8.44 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 4
Valuation
P/E -7.5×
FY 2019 5y median -8.7× FY 2025
P/S 85.5×
FY 2019 5y median 85.5× FY 2025
P/B 0.9×
FY 2019 5y median 1.7× FY 2025
P/FCF -10.3×
FY 2019 5y median -11.1× FY 2025
EV/EBITDA -7.4×
FY 2019 5y median -8.5× FY 2025
EV/Sales 82.5×
FY 2019 5y median 82.5× FY 2025
FCF Yield -9.7%
FY 2019 5y median -9.0% FY 2025
Profitability
Gross Margin 79.7%
FY 2019 5y median 79.7% FY 2025
Operating Margin -1576.7%
FY 2019 5y median -905.4% FY 2025
Net Margin -1136.3%
FY 2019 5y median -732.2% FY 2025
ROE -11.9%
FY 2019 5y median -11.9% FY 2025
ROIC -16.0%
FY 2019 5y median -16.0% FY 2025
ROA -11.3%
FY 2019 5y median -11.3% FY 2025
Growth (YoY)
Revenue -5.6%
FY 2019 FY 2025
Operating Income -59.5%
FY 2019 FY 2025
EPS (diluted) -43.0%
FY 2019 FY 2025
Free Cash Flow -88.5%
FY 2019 FY 2025
Financial Health
Current Ratio 39.0×
FY 2019 5y median 29.5× FY 2025
Quick Ratio 39.0×
FY 2019 5y median 29.5× FY 2025
Debt / Equity 0.0×
FY 2019 5y median 0.0× FY 2025
Net Debt / EBITDA 0.3×
FY 2019 5y median 0.4× FY 2025
Interest Coverage 0.0×
FY 2019 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31